65 related articles for article (PubMed ID: 22193519)
1. Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Geng JH; Lin VC; Yu CC; Huang CY; Yin HL; Chang TY; Lu TL; Huang SP; Bao BY
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27898031
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Pu YS; Hsieh CJ; Bao BY
Ann Oncol; 2012 Mar; 23(3):707-713. PubMed ID: 21652578
[TBL] [Abstract][Full Text] [Related]
3. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
[TBL] [Abstract][Full Text] [Related]
4.
Sissung TM; Lochrin S; Liu T; Schmidt K; Strope J; Risdon E; Choo-Wosoba H; Venzon DJ; Lassoued W; Sater HA; Walter-Rodriguez B; Price DK; Figg WD
Anticancer Res; 2023 Sep; 43(9):4023-4030. PubMed ID: 37648321
[TBL] [Abstract][Full Text] [Related]
5. Family Wellbeing and Sexual Health of Patients Receiving Treatment for Prostate Cancer.
Rio CJ; Goto T; Hsiao CP; Ross ALR; Saligan LN
Cancer Manag Res; 2023; 15():1197-1206. PubMed ID: 37929256
[TBL] [Abstract][Full Text] [Related]
6. A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer.
Huang EY; Chang YJ; Huang SP; Lin VC; Yu CC; Huang CY; Yin HL; Chang TY; Lu TL; Bao BY
J Cell Mol Med; 2018 Jul; 22(7):3661-3670. PubMed ID: 29682886
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor rs2228570 polymorphism is associated with LH levels in men exposed to anabolic androgenic steroids.
Björkhem-Bergman L; Lehtihet M; Rane A; Ekström L
BMC Res Notes; 2018 Jan; 11(1):51. PubMed ID: 29351807
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges.
Mondul AM; Weinstein SJ; Layne TM; Albanes D
Epidemiol Rev; 2017 Jan; 39(1):28-48. PubMed ID: 28486651
[TBL] [Abstract][Full Text] [Related]
9. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis.
Vaughan-Shaw PG; O'Sullivan F; Farrington SM; Theodoratou E; Campbell H; Dunlop MG; Zgaga L
Br J Cancer; 2017 Apr; 116(8):1092-1110. PubMed ID: 28301870
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival.
Bao BY; Lin VC; Yu CC; Yin HL; Chang TY; Lu TL; Lee HZ; Pao JB; Huang CY; Huang SP
Sci Rep; 2016 Feb; 6():22124. PubMed ID: 26902966
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation: effect on prostate cancer.
Sissung TM; Price DK; Del Re M; Ley AM; Giovannetti E; Figg WD; Danesi R
Biochim Biophys Acta; 2014 Dec; 1846(2):446-56. PubMed ID: 25199985
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.
Yu CC; Huang SP; Lee YC; Huang CY; Liu CC; Hour TC; Huang CN; You BJ; Chang TY; Huang CH; Bao BY
PLoS One; 2013; 8(1):e54627. PubMed ID: 23359804
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.
Huang SP; Bao BY; Hour TC; Huang CY; Yu CC; Liu CC; Lee YC; Huang CN; Pao JB; Huang CH
PLoS One; 2012; 7(7):e41219. PubMed ID: 22844442
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer.
Pao JB; Yang YP; Huang CN; Huang SP; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Huang CY; Bao BY
World J Urol; 2013 Apr; 31(2):281-7. PubMed ID: 22193519
[TBL] [Abstract][Full Text] [Related]
15. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
16. Association of the BsmI, ApaI, TaqI, Tru9I and FokI Polymorphisms of the Vitamin D Receptor Gene with Nephrolithiasis in the Turkish Population.
Cakir OO; Yilmaz A; Demir E; Incekara K; Kose MO; Ersoy N
Urol J; 2016 Mar; 13(1):2509-18. PubMed ID: 26945655
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review.
Chen L; Davey Smith G; Evans DM; Cox A; Lawlor DA; Donovan J; Yuan W; Day IN; Martin RM; Lane A; Rodriguez S; Davis M; Zuccolo L; Collin SM; Hamdy F; Neal D; Lewis SJ
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2874-81. PubMed ID: 19861519
[TBL] [Abstract][Full Text] [Related]
19. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
